Advancements in prostate cancer diagnosis: The role of medical imaging and AI
Thursday, June 9th, 2022
4 PM CEST
Prostate cancer is the second most common cancer in men worldwide and the second cause of death. The global burden of prostate cancer is expected to grow by over two million cases by 2040 due to the aging population and the increasing number of men diagnosed with this disease. Despite the progress made in diagnosing and treating this disease, prostate cancer remains a significant medical issue for men.
Magnetic resonance imaging (MRI), as a diagnostic tool, is still regarded as the most accurate method for identifying prostate cancer. Compared to a systematic biopsy, this method significantly increases the number of cancer cases detected.
To address the complexity of prostate cancer diagnosis, Quibim brings together international experts to discuss the use of MRI as a diagnostic tool and the potential applications of Artificial Intelligence (AI) in the detection and drug discovery process.
This webinar aims to:
- Brief on clinically significant prostate cancer predictive models.
- Introduce new techniques for imaging diagnosis in prostate cancer (new biomarkers, contrast agents, and radiotracer [PET/PSMA])
- The role of AI in the diagnosis of prostate cancer.
- To address the potential applications of AI for the development of new treatments for prostate cancer.
Head of North America at Quibim
Mark has served as a business leader in prostate imaging AI for the last 5 years. He implemented new prostate AI technologies at internationally renowned institutions such as Mass General Hospital, MD Anderson Cancer Center, and Mayo Clinic. He earned a BA at Wesleyan University and an MBA at UCLA.
Meet the speakers:
Dr. Rajan T. Gupta
Chief, Abdominal Imaging, Duke University Medical Center
Chief of Abdominal Imaging at Duke University Medical Center and an international expert in prostate MRI. He has published extensively in the field of prostate cancer and over 125 times, has been an invited national and international speaker at national meetings, universities and congresses. Much of his work focuses on improving the detection and characterization of prostate cancer using cutting-edge imaging techniques.
Dr. Juan Morote Robles
Professor of Urology, Vall d´Hebron School of Medicine, Universitat Autònoma de Barcelona
Professor of Urology at Vall d´Hebron Medical School, Autónoma University of Barcelona. His area of interest has been prostate cancer from the last 30 years. During the last five years he has been involved in the development and validation of the new Barcelona risk calculator of csPCa, and now he is working to improve the prediction of csPCa from radiogenomics.
Chief Technology Officer at Quibim
Bas has a dual masters’ degree in Physics & Biophysics and a Ph.D. in Physics from Radboud University in Nijmegen, the Netherlands. For over a decade, Bas worked for Philips Digital and Computational Pathology. As co-founder and CTO of the entity, he brought the world’s first FDA-approved digital pathology solution for primary diagnosis from ideation to a global market leader in digital pathology.